CRISPR Therapeutics Stock Could Be Undervalued Despite Recent Data, Analysts Suggest
Trendline

CRISPR Therapeutics Stock Could Be Undervalued Despite Recent Data, Analysts Suggest

What's Happening? CRISPR Therapeutics (CRSP) is currently trading at US$40.15, significantly below the analyst consensus fair value of around $74.33, suggesting it could be 46% undervalued. This assessment comes despite recent clinical data, including new Phase 1b results for CTX310 in severe hypert
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.